Parkin protects against the toxicity associated with mutant α-Synuclein: Proteasome dysfunction selectively affects catecholaminergic neurons

Neuron

Volumn 36, Issue 6, 2002, Pages 1007-1019

  Petrucelli, Leonard ^a   O'Farrell, Casey ^a   Lockhart, Paul J ^a   Baptista, Melisa ^c   Kehoe, Kathryn ^a   Vink, Liselot ^a   Choi, Peter ^b   Wolozin, Benjamin ^b   Farrer, Matthew ^a   Hardy, John ^c   Cookson, Mark R ^c  

^a MAYO CLINIC   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; MUTANT PROTEIN; PARKIN; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN PROTEIN LIGASE;

ARTICLE; BRAIN CELL; CATECHOLAMINE NERVE CELL; CELL CULTURE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MESENCEPHALON; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 0037137702     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(02)01125-X     Document Type: Article

References (53)

1. Ancolio K., Alves da Costa C., Ueda K., Checler F. Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci. Lett. 285:2000;79-82.
2. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555.
3. Bennett M.C., Bishop J.F., Leng Y., Chock P.B., Chase T.N., Mouradian M.M. Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274:1999;33855-33858.
4. Braak H., Braak E. Pathoanatomy of Parkinson's disease. J. Neurol. Suppl. 247:2000;3-10.
5. Burke R.E., Antonelli M., Sulzer D. Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. J. Neurochem. 71:1998;517-525.
6. Chung K.K., Zhang Y., Lim K.L., Tanaka Y., Huang H., Gao J., Ross C.A., Dawson V.L., Dawson T.M. Parkin ubiquitinates the α-synuclein-interacting protein, synphilin-1. implications for Lewy-body formation in Parkinson disease Nat. Med. 7:2001;1144-1150.
7. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease. implications for pathogenesis and therapy Proc. Natl. Acad. Sci. USA. 97:2000;571-576.
8. Conway K.A., Rochet J.-C., Bieganski R.M., Lansbury P.T. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science. 294:2001;1346-1349.
9. Cookson M.R., Ince P.G., Shaw P.J. Peroxynitrite and hydrogen peroxide induced cell death in the NSC34 neuroblastoma x spinal cord cell line. Role of poly(ADP-ribose) polymerase J. Neurochem. 70:1998;501-508.
10. Coopersmith R., Neve R.L. Expression of multiple proteins within single primary cortical neurons using a replication deficient HSV vector. Biotechniques. 27:1999;1156-1160.
11. Ellis R.J. Macromolecular crowding. an important but neglected aspect of the intracellular environment Curr. Opin. Struct. Biol. 11:2001;114-119.
12. Farrer M., Destee T., Becquet E., Wavrant-De Vrieze F., Mouroux V., Richard F., Defebvre L., Lincoln S., Hardy J., Amouyel P., Chartier-Harlin M. Linkage exclusion in French families with probable Parkinson's disease. Mov. Disord. 15:2000;1075-1083.
13. Farrer M., Chan P., Chen R., Tan L., Lincoln S., Hernandez D., Forno L., Gwinn-Hardy K., Petrucelli L., Hussey J.et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50:2001;293-300.
14. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature. 404:2000;394-398.
15. Ghee M., Fournier A., Mallet J. Rat alpha-synuclein interacts with tat binding protein 1, a component of the 26S proteasomal complex. J. Neurochem. 75:2000;2221-2224.
16. Gilon T., Chomsky O., Kulka R.G. Degradation signals for ubiquitin system proteolysis in Saccharomyces cerevisiae. EMBO J. 17:1998;2759-2766.
17. Hashimoto M., Rockenstein E., Mante M., Mallory M., Masliah E. beta-Synuclein inhibits alpha-synuclein aggregation. a possible role as an anti-parkinsonian factor Neuron. 32:2001;213-223.
18. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425-479.
19. Imai Y., Soda M., Takahashi R. Parkin supresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275:2000;35661-35664.
20. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell. 105:2001;891-902.
21. Junn E., Mouradian M.M. Human a-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320:2002;146-150.
22. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J., Bjorklund A. Parkinson-like neurodegeneration induced by the targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22:2002;2780-2791.
23. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392:1998;605-608.
24. Ko L., Mehta N.D., Farrer M., Easson C., Hussey J., Yen S., Hardy J., Yen S.H. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. J. Neurochem. 75:2000;2546-2554.
25. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18:1998;106-108.
26. Lee H.J., Shin S.Y., Choi C., Lee Y.H., Lee S.J. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277:2001;5411-5417. a.
27. Lee M., Hyun D., Halliwell B., Jenner P. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J. Neurochem. 76:2001;998-1009. b.
28. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T.et al. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452.
29. Maraganore D.M., Farrer M.J., Hardy J.A., Lincoln S.J., McDonnell S.K., Rocca W.A. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology. 53:1999;1858-1860.
30. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in α-synuclein mice. implications for neurodegenerative disorders Science. 287:2000;1265-1269.
31. Matsuoka Y., Vila M., Lincoln S., McCormack A., Picciano M., LaFrancois J., Yu X., Dickson D., Langston W.J., McGowan E.et al. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8:2001;535-539.
32. McNaught K.S., Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297:2001;191-194.
33. McNaught K.S., Bjorklund L.M., Belizaire R., Isacson O., Jenner P., Olanow C.W. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport. 13:2002;1437-1441.
34. Mena M.A., Khan U., Togasaki D.M., Sulzer D., Epstein C.J., Przedborski S. Effects of wild-type and mutated copper/zinc superoxide dismutase on neuronal survival and L-DOPA-induced toxicity in postnatal midbrain culture. J. Neurochem. 69:1997;21-33.
35. Murphy D.D., Rueter S.M., Trojanowski J.Q., Lee V.M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20:2000;3214-3220.
36. Neve R.L., Howe J.R., Hong S., Kalb R.G. Introduction of the glutamate receptor subunit 1 into motor neurons in vitro and in vivo using a recombinant herpes simplex virus. Neuroscience. 79:1997;435-447.
37. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farrer M., Wolozin B. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20:2000;6048-6054.
38. Pakkenberg B., Moller A., Gundersen H.J., Mouritzen Dam A., Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J. Neurol. Neurosurg. Psychiatry. 54:1991;30-33.
39. Paxinou E., Chen Q., Weisse M., Giasson B.I., Norris E.H., Rueter S.M., Trojanowski J.Q., Lee V.M., Ischiropoulos H. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21:2001;8053-8061.
40. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R.et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
41. Rathke-Hartlieb S., Kahle P.J., Neumann M., Ozmen L., Haid S., Okochi M., Haass C., Schulz J.B. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J. Neurochem. 77:2001;1181-1184.
42. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimuzu N., Iwai K., Chiba T., Tanaka K., Suzuki T. Familial parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25:2000;302-305.
43. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of α-synuclein by parkin from human brain. implications for Parkinson's disease Science. 293:2001;263-269.
44. Shtilerman M.D., Ding T.T., Lansbury P.T. Molecular crowding accelerates fibrillization of alpha-synuclein. could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry. 41:2002;3855-3860.
45. Stefanis L., Larsen K.E., Rideout H.J., Sulzer D., Greene L.A. Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21:2001;9549-9560.
46. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A.L., Dawson V., Dawson T.M., Ross C.A. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10:2001;919-926.
47. Tofaris G.K., Layfield R., Spillantini M.G. α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509:2001;22-26.
48. Uversky V.N., Cooper E.M., Bower K.S., Li J., Fink A.L. Accelerated α-synuclein fibrillation in crowded milieu. FEBS Lett. 515:2002;99-103.
49. VanDerPutten H., Widerhold K.-H., Probst A., Barbieri S., Misti C., Danner S., Kauffmann S., Hofele K., Spooren W.P., Ruegg M.A.et al. Neuropathology in mice expressing human α-synuclein. J. Neurosci. 20:2000;6021-6029.
50. Wintermeyer P., Kruger R., Kuhn W., Muller T., Woitalla D., Berg D., Becker G., Leroy E., Polymeropoulos M., Berger K.et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport. 11:2000;2079-2082.
51. Xu J., Kao S.-Y., Lee F.J.S., Song W., Jin L.-W., Yankner B.A. Dopamine-dependent neurotoxicity of α-synuclein. a mechanism for selective neurodegeneration in Parkinson disease Nat. Med. 8:2002;600-606.
52. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., Dawson T.M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. USA. 97:2000;13354-13359.
53. Zhou W., Hurlbert M.S., Schaack J., Prasad K.N., Freed C.R. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 866:2000;33-43.